Organon & Co (OGN)
Operating return on assets (Operating ROA)
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating income (ttm) | US$ in thousands | -930,000 | -882,000 | -629,000 | -619,000 | -394,000 | -306,000 | -151,000 | 3,000 | -83,000 | |||
Total assets | US$ in thousands | 12,058,000 | 11,012,000 | 10,979,000 | 10,763,000 | 10,955,000 | 10,437,000 | 10,614,000 | 10,597,000 | 10,681,000 | 11,335,000 | 10,908,000 | 9,642,000 |
Operating ROA | -7.71% | -8.01% | -5.73% | -5.75% | -3.60% | -2.93% | -1.42% | 0.03% | -0.78% |
December 31, 2023 calculation
Operating ROA = Operating income (ttm) ÷ Total assets
= $-930,000K ÷ $12,058,000K
= -7.71%
Organon & Co.'s operating return on assets (operating ROA) has shown a decreasing trend over the past quarters based on the provided data. The operating ROA decreased from 17.78% in Q1 2022 to 11.01% in Q4 2023. This declining trend suggests that the company may be experiencing challenges in generating operating profits relative to its assets. It is important for Organon & Co. to closely monitor and analyze the factors contributing to this decline in operating ROA in order to make informed decisions to improve overall performance and efficiency.
Peer comparison
Dec 31, 2023
Company name
Symbol
Operating ROA
Organon & Co
OGN
-7.71%
Abbott Laboratories
ABT
8.85%
AbbVie Inc
ABBV
9.47%
Alkermes Plc
ALKS
17.02%
Amphastar P
AMPH
13.02%
ANI Pharmaceuticals Inc
ANIP
5.19%
Arcus Biosciences Inc
RCUS
-31.05%
Biomarin Pharmaceutical Inc
BMRN
2.72%
Bristol-Myers Squibb Company
BMY
-9.99%
Catalent Inc
CTLT
-7.68%
Catalyst Pharmaceuticals Inc
CPRX
18.47%